Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

被引:926
作者
Roth, BL [1 ]
Sheffler, DJ [1 ]
Kroeze, WK [1 ]
机构
[1] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1038/nrd1346
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Most common central nervous system disorders-such as depression, bipolar disorder and schizophrenia-seem to be polygenic in origin, and the most effective medications have exceedingly complex pharmacologies. Attempts to develop more effective treatments for diseases such as schizophrenia and depression by discovering drugs selective for single molecular targets (that is, 'magic bullets') have, not surprisingly, been largely unsuccessful. Here we propose that designing selectively non-selective drugs (that is, 'magic shotguns') that interact with several molecular targets will lead to new and more effective medications for a variety of central nervous system disorders.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 63 条
  • [1] ALTAR CA, 1986, BRAIN RES BULL, V16, P517
  • [2] A single-site, double-blind, placebo-controlled, dose-ranging study of YKP10A - a putative, new antidepressant
    Amsterdam, JD
    Brunswick, DJ
    Hundert, M
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2002, 26 (7-8) : 1333 - 1338
  • [3] Meta-analytical studies on new antidepressants
    Anderson, IM
    [J]. BRITISH MEDICAL BULLETIN, 2001, 57 : 161 - 178
  • [4] Dopamine agonists in schizophrenia: A review
    Benkert, O
    MullerSiecheneder, F
    Wetzel, H
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1995, 5 : 43 - 53
  • [5] The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial
    Berman, RM
    Anand, A
    Cappiello, A
    Miller, HL
    Hu, XS
    Oren, DA
    Charney, DS
    [J]. BIOLOGICAL PSYCHIATRY, 1999, 45 (09) : 1170 - 1177
  • [6] Animal models - Can a mouse be standardized?
    Bohannon, J
    [J]. SCIENCE, 2002, 298 (5602) : 2320 - 2321
  • [7] Briley Mike, 2003, Curr Opin Investig Drugs, V4, P42
  • [8] Bristow LJ, 1997, TRENDS PHARMACOL SCI, V18, P186, DOI 10.1016/S0165-6147(97)90618-0
  • [9] In need of high-throughput behavioral systems
    Brunner, D
    Nestler, E
    Leahy, E
    [J]. DRUG DISCOVERY TODAY, 2002, 7 (18) : S107 - S112
  • [10] Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors
    Burris, KD
    Molski, TF
    Xu, C
    Ryan, E
    Tottori, K
    Kikuchi, T
    Yocca, FD
    Molinoff, PB
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (01) : 381 - 389